Psychogenic cough: a diagnosis of exclusion.

Cough is the most common respiratory symptom and a common reason for consultation in both primary care and emergency departments, as a result of family concerns. We report an 11-year-old girl who complains of constant cough episode for 4 hours without any rest. After sequential treatment with nebulized salbutamol and budesonide, dexamethasone, codeine, and midazolam, the patient showed transient improvement, with cough disappearing altogether, but 10 minutes later, it started over with the same intensity from the beginning. When she got distracted and talked, the access decreased, starting again when the word "cough" or similar terms were mentioned in front of her. She remained asymptomatic for 2 hours, after which her symptoms began similarly to the initial, coinciding with taking 1 tablet of clarithromycin, so it was decided to start a continuous infusion of midazolam, with the cough disappearing completely after 15 minutes of starting the infusion. One hour after starting the infusion, the child fell asleep. At waking, the cough had disappeared. She continued treatment with oral codeine for 3 days, showing no relapse. It is important to include psychogenic cough in the differential diagnosis of persistent or recurrent chronic cough and asthma that is difficult to control and communicate that diagnostic criteria are based on indicative symptoms (cough access only when awake), with normal radiology, spirometry, and bronchoscopy, to avoid misdiagnosis and inadequate pharmacological actions. Successful treatment is based on recognizing the underlying cause and use of different forms of cognitive-behavioral therapies that aim to break the habit.

Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP.

Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014-2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6-8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn's Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (µg/g) decreased significantly after EEN (830 [IQR 500-1800] to 256 [IQR 120-585] p < 0.0001). Patients with wPCDAI ≤ 57.5, FC < 500 µg/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6-8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn's disease regardless of the location of disease and disease activity.